Global Gastrointestinal Stromal Tumors Therapeutics Market Growth (Status and Outlook) 2022-2028
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Gastrointestinal Stromal Tumors Therapeutics Market Size 2017-2028
- 2.1.2 Gastrointestinal Stromal Tumors Therapeutics Market Size CAGR by Region 2017 VS 2022 VS 2028
- 2.2 Gastrointestinal Stromal Tumors Therapeutics Segment by Type
- 2.2.1 Oral
- 2.2.2 Non-oral
- 2.3 Gastrointestinal Stromal Tumors Therapeutics Market Size by Type
- 2.3.1 Gastrointestinal Stromal Tumors Therapeutics Market Size CAGR by Type (2017 VS 2022 VS 2028)
- 2.3.2 Global Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Type (2017-2022)
- 2.4 Gastrointestinal Stromal Tumors Therapeutics Segment by Application
- 2.4.1 Hospital
- 2.4.2 Clinic
- 2.4.3 Others
- 2.5 Gastrointestinal Stromal Tumors Therapeutics Market Size by Application
- 2.5.1 Gastrointestinal Stromal Tumors Therapeutics Market Size CAGR by Application (2017 VS 2022 VS 2028)
- 2.5.2 Global Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Application (2017-2022)
3 Gastrointestinal Stromal Tumors Therapeutics Market Size by Player
- 3.1 Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Players
- 3.1.1 Global Gastrointestinal Stromal Tumors Therapeutics Revenue by Players (2020-2022)
- 3.1.2 Global Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Players (2020-2022)
- 3.2 Global Gastrointestinal Stromal Tumors Therapeutics Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Gastrointestinal Stromal Tumors Therapeutics by Regions
- 4.1 Gastrointestinal Stromal Tumors Therapeutics Market Size by Regions (2017-2022)
- 4.2 Americas Gastrointestinal Stromal Tumors Therapeutics Market Size Growth (2017-2022)
- 4.3 APAC Gastrointestinal Stromal Tumors Therapeutics Market Size Growth (2017-2022)
- 4.4 Europe Gastrointestinal Stromal Tumors Therapeutics Market Size Growth (2017-2022)
- 4.5 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size Growth (2017-2022)
5 Americas
- 5.1 Americas Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2017-2022)
- 5.2 Americas Gastrointestinal Stromal Tumors Therapeutics Market Size by Type (2017-2022)
- 5.3 Americas Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2017-2022)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2017-2022)
- 6.2 APAC Gastrointestinal Stromal Tumors Therapeutics Market Size by Type (2017-2022)
- 6.3 APAC Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2017-2022)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
7 Europe
- 7.1 Europe Gastrointestinal Stromal Tumors Therapeutics by Country (2017-2022)
- 7.2 Europe Gastrointestinal Stromal Tumors Therapeutics Market Size by Type (2017-2022)
- 7.3 Europe Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2017-2022)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics by Region (2017-2022)
- 8.2 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size by Type (2017-2022)
- 8.3 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2017-2022)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Global Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.1 Global Gastrointestinal Stromal Tumors Therapeutics Forecast by Regions (2023-2028)
- 10.1.1 Global Gastrointestinal Stromal Tumors Therapeutics Forecast by Regions (2023-2028)
- 10.1.2 Americas Gastrointestinal Stromal Tumors Therapeutics Forecast
- 10.1.3 APAC Gastrointestinal Stromal Tumors Therapeutics Forecast
- 10.1.4 Europe Gastrointestinal Stromal Tumors Therapeutics Forecast
- 10.1.5 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Forecast
- 10.2 Americas Gastrointestinal Stromal Tumors Therapeutics Forecast by Country (2023-2028)
- 10.2.1 United States Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.2.2 Canada Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.2.3 Mexico Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.2.4 Brazil Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.3 APAC Gastrointestinal Stromal Tumors Therapeutics Forecast by Region (2023-2028)
- 10.3.1 China Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.3.2 Japan Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.3.3 Korea Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.3.4 Southeast Asia Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.3.5 India Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.3.6 Australia Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.4 Europe Gastrointestinal Stromal Tumors Therapeutics Forecast by Country (2023-2028)
- 10.4.1 Germany Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.4.2 France Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.4.3 UK Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.4.4 Italy Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.4.5 Russia Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.5 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Forecast by Region (2023-2028)
- 10.5.1 Egypt Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.5.2 South Africa Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.5.3 Israel Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.5.4 Turkey Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.5.5 GCC Countries Gastrointestinal Stromal Tumors Therapeutics Market Forecast
- 10.6 Global Gastrointestinal Stromal Tumors Therapeutics Forecast by Type (2023-2028)
- 10.7 Global Gastrointestinal Stromal Tumors Therapeutics Forecast by Application (2023-2028)
11 Key Players Analysis
- 11.1 Ascentage Pharma Group International
- 11.1.1 Ascentage Pharma Group International Company Information
- 11.1.2 Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Product Offered
- 11.1.3 Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
- 11.1.4 Ascentage Pharma Group International Main Business Overview
- 11.1.5 Ascentage Pharma Group International Latest Developments
- 11.2 Bayer AG
- 11.2.1 Bayer AG Company Information
- 11.2.2 Bayer AG Gastrointestinal Stromal Tumors Therapeutics Product Offered
- 11.2.3 Bayer AG Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
- 11.2.4 Bayer AG Main Business Overview
- 11.2.5 Bayer AG Latest Developments
- 11.3 Blueprint Medicines Corp
- 11.3.1 Blueprint Medicines Corp Company Information
- 11.3.2 Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Product Offered
- 11.3.3 Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
- 11.3.4 Blueprint Medicines Corp Main Business Overview
- 11.3.5 Blueprint Medicines Corp Latest Developments
- 11.4 Bristol Myers Squibb Co.
- 11.4.1 Bristol Myers Squibb Co. Company Information
- 11.4.2 Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Product Offered
- 11.4.3 Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
- 11.4.4 Bristol Myers Squibb Co. Main Business Overview
- 11.4.5 Bristol Myers Squibb Co. Latest Developments
- 11.5 Deciphera Pharmaceuticals Inc
- 11.5.1 Deciphera Pharmaceuticals Inc Company Information
- 11.5.2 Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Product Offered
- 11.5.3 Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
- 11.5.4 Deciphera Pharmaceuticals Inc Main Business Overview
- 11.5.5 Deciphera Pharmaceuticals Inc Latest Developments
- 11.6 Immunicum AB
- 11.6.1 Immunicum AB Company Information
- 11.6.2 Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Product Offered
- 11.6.3 Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
- 11.6.4 Immunicum AB Main Business Overview
- 11.6.5 Immunicum AB Latest Developments
- 11.7 Novartis AG
- 11.7.1 Novartis AG Company Information
- 11.7.2 Novartis AG Gastrointestinal Stromal Tumors Therapeutics Product Offered
- 11.7.3 Novartis AG Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
- 11.7.4 Novartis AG Main Business Overview
- 11.7.5 Novartis AG Latest Developments
- 11.8 Pfizer Inc.
- 11.8.1 Pfizer Inc. Company Information
- 11.8.2 Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Product Offered
- 11.8.3 Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
- 11.8.4 Pfizer Inc. Main Business Overview
- 11.8.5 Pfizer Inc. Latest Developments
- 11.9 Sun Pharmaceutical Industries Ltd
- 11.9.1 Sun Pharmaceutical Industries Ltd Company Information
- 11.9.2 Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Product Offered
- 11.9.3 Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
- 11.9.4 Sun Pharmaceutical Industries Ltd Main Business Overview
- 11.9.5 Sun Pharmaceutical Industries Ltd Latest Developments
- 11.10 Xencor Inc.
- 11.10.1 Xencor Inc. Company Information
- 11.10.2 Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Product Offered
- 11.10.3 Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
- 11.10.4 Xencor Inc. Main Business Overview
- 11.10.5 Xencor Inc. Latest Developments
12 Research Findings and Conclusion
The global market for Gastrointestinal Stromal Tumors Therapeutics is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Gastrointestinal Stromal Tumors Therapeutics market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Gastrointestinal Stromal Tumors Therapeutics market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Gastrointestinal Stromal Tumors Therapeutics market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Gastrointestinal Stromal Tumors Therapeutics market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Gastrointestinal Stromal Tumors Therapeutics players cover Ascentage Pharma Group International, Bayer AG, Blueprint Medicines Corp, Bristol Myers Squibb Co. and Deciphera Pharmaceuticals Inc, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Gastrointestinal Stromal Tumors Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Gastrointestinal Stromal Tumors Therapeutics market, with both quantitative and qualitative data, to help readers understand how the Gastrointestinal Stromal Tumors Therapeutics market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Gastrointestinal Stromal Tumors Therapeutics market and forecasts the market size by Type (Oral and Non-oral,), by Application (Hospital, Clinic and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Oral
Non-oral
Segmentation by application
Hospital
Clinic
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Ascentage Pharma Group International
Bayer AG
Blueprint Medicines Corp
Bristol Myers Squibb Co.
Deciphera Pharmaceuticals Inc
Immunicum AB
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd
Xencor Inc.
Chapter Introduction
Chapter 1: Scope of Gastrointestinal Stromal Tumors Therapeutics, Research Methodology, etc.
Chapter 2: Executive Summary, global Gastrointestinal Stromal Tumors Therapeutics market size and CAGR, Gastrointestinal Stromal Tumors Therapeutics market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Gastrointestinal Stromal Tumors Therapeutics revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Gastrointestinal Stromal Tumors Therapeutics revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Gastrointestinal Stromal Tumors Therapeutics market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Ascentage Pharma Group International, Bayer AG, Blueprint Medicines Corp, Bristol Myers Squibb Co., Deciphera Pharmaceuticals Inc, Immunicum AB, Novartis AG, Pfizer Inc. and Sun Pharmaceutical Industries Ltd, etc.
Chapter 14: Research Findings and Conclusion